Efficacy and Safety Assessment of Antifungal Prophylaxis with Posaconazole Using Therapeutic Drug Monitoring in Pediatric Patients with Oncohematological Disorders—A Single-Centre Study
Authors:
- Karolina LiszkaKLKarolina Liszka
- Paweł MarschollekPMPaweł Marschollek
- Dawid PrzystupskiDPDawid Przystupski
- Jowita FrączkiewiczJFJowita Frączkiewicz
- Monika Mielcarek-SiedziukMMMonika Mielcarek-Siedziuk
- Igor OlejnikIOIgor Olejnik
- Zuzanna GamrotZGZuzanna Gamrot
- Natalia HazeNHNatalia Haze
- Agnieszka KwellaAKAgnieszka Kwella
- Paulina ZalewskaPZPaulina Zalewska
- Matylda ResztakMRMatylda Resztak
- Marek UssowiczMarek Ussowicz
Open Access
- 6 January 2025
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (1) , 38
Abstract
Introduction: Posaconazole is recommended for prophylaxis in pediatric immunocompromised patients. Due to its variability in bioavailability and drug-to-drug interactions, EBMT recommends regimens based on therapeutic drug monitoring (TDM). Materials and methods: In total, 171 oncohematological pediatric patients on posaconazole prophylaxis were included. Full pharmacokinetic posaconazole profiles were assessed in 51 children. The efficacy and safety of posaconazole was evaluated by measuring the drug concentration, with dose modification attempted in patients with suboptimal results. The influence of modifying factors on the posaconazole plasma concentration (PPC) was investigated. Results: An insufficient PPC was the main issue, but no significant increase in prophylaxis failure was reported. The modification of the dosage resulted in the optimization of PPC in 50% of patients. No significant correlation between age, gender, diagnosis or the posaconazole dosage and the PPC was found. HCT, total parenteral nutrition and diarrhea were associated with a lower PPC. Hypoalbuminemia was related to both higher and lower PPC. The concomitant administration of specified drugs significantly impacted the PPC. Conclusions: TDM allows the identification of patients receiving non-optimal treatment and offers an opportunity to improve the efficacy and safety of the therapy. However, further research involving larger patient groups and longer observation periods are needed to determine the optimal dosing and target PPC in pediatric patients.Keywords
Funding Information
- Foundation’s ‘Na Ratunek Dzieciom z Chorobą Nowotworową’ (FNRD.C200.20.006 (B/01/11/2020))
This publication has 26 references indexed in Scilit:
- 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantationThe Lancet Oncology, 2021
- Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factorsBone Marrow Transplantation, 2019
- Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to PolypharmacotherapyIndian Journal of Hematology and Blood Transfusion, 2019
- Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseJournal of Antimicrobial Chemotherapy, 2017
- Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical MycologyJournal of Antimicrobial Chemotherapy, 2013
- Lack of Evidence for Exposure–Response Relationship in the Use of Posaconazole as Prophylaxis Against Invasive Fungal InfectionsClinical Pharmacology & Therapeutics, 2011
- Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in PlasmaClinical Pharmacology & Therapeutics, 2010
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal InfectionsClinical Infectious Diseases, 2006